Mammoth Biosciences
Siang Chin currently serves as General Counsel at Mammoth Biosciences since November 2022. Prior to this, Siang held roles at Intuitive Surgical, Inc. as Vice President and Assistant General Counsel from January 2019 to November 2022, and at Varian Medical Systems as Vice President and Associate General Counsel from January 2017 to December 2018. Siang was also Senior Vice President and General Counsel at Affymetrix, Inc. from 2007 to 2016, where key contributions included leading the company through significant transformation, resulting in a growth in stock price and eventual acquisition by Thermo Fisher. Earlier experience includes positions as an Associate at Shearman and Sterling and Slaughter and May. Siang holds a Master of Laws (LLM) from Georgetown University and a Bachelor of Laws (LLB) from King's College London.
This person is not in any offices
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.